| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Grazia Dell'Agnello, Alessandro Zuddas, Gabriele Masi, Paolo Curatolo, Dante Besana, Andrea Ross. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689165. |
atomoxetine is a specific, noradrenergic reuptake inhibitor that provides an effective treatment option for patients with adhd and co-morbid conditions. |
2009-11-09 |
2023-08-12 |
Not clear |
| Julie A Dopheide, Steven R Pliszk. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. vol 29. issue 6. 2009-08-06. PMID:19476419. |
in patients with adhd, neurobiologic research has shown a lack of connectivity in key brain regions, inhibitory control deficits, delayed brain maturation, and noradrenergic and dopaminergic dysfunction in multiple brain regions. |
2009-08-06 |
2023-08-12 |
Not clear |
| Florence Lev. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. The Australian and New Zealand journal of psychiatry. vol 43. issue 2. 2009-07-13. PMID:19153917. |
the aim of the present study was to review the dopamine theory of attention-deficit-hyperactivity disorder (adhd), in light of recent use of noradrenergic therapies. |
2009-07-13 |
2023-08-12 |
human |
| Laura Marsh, Kevin Biglan, Melissa Gerstenhaber, James R William. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Movement disorders : official journal of the Movement Disorder Society. vol 24. issue 2. 2009-06-08. PMID:19025777. |
given the role of noradrenergic pathology in ed, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (adhd), may be a potential treatment for pd-related ed. |
2009-06-08 |
2023-08-12 |
Not clear |
| San-Duo Jiang, Mei He, Yi-Ping Qian, Dong-Xian Wang, Ye Zhang, Fei Li, Hong-Jun Tian, Ren-E Xin, Guo-Mei Tang, Xiao-Dong W. [Genome-wide search for linkage to attention deficit hyperactivity disorder (ADHD) on the X chromosome]. Yi chuan = Hereditas. vol 28. issue 1. 2009-04-16. PMID:16469712. |
molecular genetic and pharmacological studies suggest the involvement of dopaminergic and noradrenergic neurotransmitter systems in adhd, e.g , several reports have found association between adhd and the dopamine receptor gene drd-4.the dopamine transporter gene dat1, and the catechol-o-methyltransferase. |
2009-04-16 |
2023-08-12 |
Not clear |
| J Biederman, Raun D Melmed, Anil Patel, Keith McBurnett, Jessica Donahue, Andrew Lyn. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS spectrums. vol 13. issue 12. 2009-03-19. PMID:19179940. |
guanfacine is a noradrenergic agonist that is believed to improve symptoms of attention-deficit/hyperactivity disorder (adhd) through selective actions at alpha2a-adrenoceptors in the prefrontal cortex. |
2009-03-19 |
2023-08-12 |
Not clear |
| Soo-Churl Cho, Jae-Won Kim, Boong-Nyun Kim, Jun-Won Hwang, Min-Sup Shin, Mira Park, Soon Ae Kim, Dae-Yeon Cho, Hee-Jeong Yoo, Un-Sun Chung, Jung-Woo Son, Tae-Won Par. Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample. Neuroscience letters. vol 446. issue 2-3. 2009-02-27. PMID:18835330. |
findings from preclinical and clinical research support the involvement of central noradrenergic dysregulation in the etiology of attention deficit hyperactivity disorder (adhd). |
2009-02-27 |
2023-08-12 |
human |
| Soo-Churl Cho, Jae-Won Kim, Boong-Nyun Kim, Jun-Won Hwang, Min-Sup Shin, Mira Park, Soon Ae Kim, Dae-Yeon Cho, Hee-Jeong Yoo, Un-Sun Chung, Jung-Woo Son, Tae-Won Par. Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample. Neuroscience letters. vol 446. issue 2-3. 2009-02-27. PMID:18835330. |
in addition, our results provide evidence that the temperament of novelty seeking and adhd might share molecular genetic characteristics related to the noradrenergic system. |
2009-02-27 |
2023-08-12 |
human |
| R Martín-González, P A González-Pérez, M Izquierdo-Hernández, S Hernández-Expósito, M A Alonso-Rodríguez, I Quintero-Fuentes, B Rubio-Morel. [Neuropsychological assessment of memory in attention deficit hyperactivity disorder: the role of executive functions]. Revista de neurologia. vol 47. issue 5. 2008-11-18. PMID:18780266. |
there is an important agreement on the consideration of attention deficit hyperactivity disorder (adhd) as a condition characterized by neurodevelopmental dysfunction of fronto-striatal dopaminergic and noradrenergic circuits with resultant executive deficits in cognitive functioning. |
2008-11-18 |
2023-08-12 |
Not clear |
| B Rubio-Morell, R Martín-González, O Herreros-Rodríguez, P González-Pérez, S Hernández-Exposito, I Quintero-Fuentes, R Gracia-Marc. [Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder]. Revista de neurologia. vol 46. issue 10. 2008-09-15. PMID:18465700. |
there is wide evidence about dopaminergic and noradrenergic mechanisms in fronto-striatal circuits which are thought to be related with attention deficit hyperactivity disorder (adhd) neurobiology. |
2008-09-15 |
2023-08-12 |
Not clear |
| Soo-Churl Cho, Jae-Won Kim, Boong-Nyun Kim, Jun-Won Hwang, Mira Park, Soon Ae Kim, Dae-Yeon Cho, Hee-Jeong Yoo, Un-Sun Chung, Jung-Woo Son, Tae-Won Par. No evidence of an association between norepinephrine transporter gene polymorphisms and attention deficit hyperactivity disorder: a family-based and case-control association study in a Korean sample. Neuropsychobiology. vol 57. issue 3. 2008-09-15. PMID:18552510. |
neurobiological and pharmacological research has suggested that dysregulation of the central noradrenergic systems might be involved in the pathophysiology of attention deficit hyperactivity disorder (adhd). |
2008-09-15 |
2023-08-12 |
Not clear |
| J W Kim, J Biederman, C L McGrath, A E Doyle, E Mick, J Fagerness, S Purcell, J W Smoller, P Sklar, S V Faraon. Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Molecular psychiatry. vol 13. issue 6. 2008-08-06. PMID:17876324. |
noradrenergic systems are critical to higher brain functions such as attention and executive function, which are defective in adhd. |
2008-08-06 |
2023-08-12 |
Not clear |
| Kerstin Malmberg, Hanna-Linn Wargelius, Paul Lichtenstein, Lars Oreland, Jan-Olov Larsso. ADHD and Disruptive Behavior scores - associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents. BMC psychiatry. vol 8. 2008-08-06. PMID:18430257. |
pharmacological and genetic studies suggest the importance of the dopaminergic, serotonergic, and noradrenergic systems in the pathogenesis of attention deficit hyperactivity disorder (adhd) and disruptive behavior disorder (dbd). |
2008-08-06 |
2023-08-12 |
Not clear |
| Li-Li Liu, Jie Yang, Ge-Fei Lei, Gui-Ju Wang, Yu-Wei Wang, Ruo-Peng Su. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Basic & clinical pharmacology & toxicology. vol 102. issue 6. 2008-06-12. PMID:18346050. |
substantial development in the pharmacological treatment for attention-deficit hyperactivity disorder (adhd) has been made recently including approval of new non-stimulant agents targeting noradrenergic, histaminergic and dopaminergic systems. |
2008-06-12 |
2023-08-12 |
rat |
| W Retz, M Rösler, C Kissling, S Wiemann, R Hünnerkopf, A Coogan, J Thome, C Freita. Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. Journal of neural transmission (Vienna, Austria : 1996). vol 115. issue 2. 2008-05-30. PMID:17994190. |
only a few studies have focused on the association of noradrenergic susceptibility genes with adhd. |
2008-05-30 |
2023-08-12 |
human |
| Vivienne Ann Russel. Reprint of "Neurobiology of animal models of attention-deficit hyperactivity disorder". Journal of neuroscience methods. vol 166. issue 2. 2008-02-14. PMID:17980763. |
however, evidence obtained from some animal models suggests that the noradrenergic and serotonergic neurotransmitter systems may be the target of drugs that ameliorate adhd symptoms. |
2008-02-14 |
2023-08-12 |
mouse |
| San-Duo Jiang, Xiao-Dong Wu, Ye Zhang, Guo-Mei Tang, Yi-Ping Qian, Dong-Xiang Wan. No association between attention-deficit hyperactivity disorder and catechol-O-methyltransferase gene in Chinese. Yi chuan xue bao = Acta genetica Sinica. vol 32. issue 8. 2008-01-31. PMID:16231731. |
since catechel-o-methyltransferase (comt) is an enzyme involved in the degradation of catecholaminergic neurotransmitters of the dopaminergic and noradrenergic systems,it is possible that comt may play a role in adhd. |
2008-01-31 |
2023-08-12 |
Not clear |
| b' Monika Dvor\\xc3\\xa1kov\\xc3\\xa1, Daniela Jezov\\xc3\\xa1, Pavol Blaz\\xc3\\xadcek, Jana Trebatick\\xc3\\xa1, Igor Skod\\xc3\\xa1cek, J\\xc3\\xa1n Suba, Waczul\\xc3\\xadkov\\xc3\\xa1 Iveta, Peter Rohdewald, Zdenka Durackov\\xc3\\xa. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (pycnogenol). Nutritional neuroscience. vol 10. issue 3-4. 2008-01-18. PMID:18019397.' |
in conclusion, the data provide further evidence for the overactivity of the noradrenergic system in adhd and demonstrate that a release may be increased, as well. |
2008-01-18 |
2023-08-12 |
Not clear |
| Michael J Frank, Amy Santamaria, Randall C O'Reilly, Erik Willcut. Testing computational models of dopamine and noradrenaline dysfunction in attention deficit/hyperactivity disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 7. 2007-08-31. PMID:17164816. |
however, other adhd effects such as erratic trial-to-trial switching and reaction time variability are not accounted for by model da mechanisms, and are instead consistent with cortical noradrenergic dysfunction and associated computational models. |
2007-08-31 |
2023-08-12 |
human |
| James M Swanso. Role of executive function in ADHD. The Journal of clinical psychiatry. vol 64 Suppl 14. 2007-08-27. PMID:14658934. |
adhd is commonly treated with behavioral therapy and noradrenergic and dopaminergic pharmacotherapy with psychostimulants such as methylphenidate and dextroamphetamine. |
2007-08-27 |
2023-08-12 |
Not clear |